Document:

BRIACELL
THERAPEUTICS CORP.

 

(the
“Company”)

 

STOCK
OPTION PLAN

 

	1.	STATEMENT
    OF PURPOSE

 

	1.1	Principal
    Purposes - The principal purposes of the Plan are to provide the Company with the advantages of the incentive inherent
    in share ownership on the part of employees, officers, directors and consultants responsible for the continued success of
    the Company; to create in such individuals a proprietary interest in, and a greater concern for, the welfare and success of
    the Company; to encourage such individuals to remain with the Company; and to attract new employees, officers, directors and
    consultants to the Company.

 

	1.2	Benefit
    to Shareholders - The Plan is expected to benefit shareholders by enabling the Company to attract and retain skilled
    and motivated personnel by offering such personnel an opportunity to share in any increase in value of the Shares resulting
    from their efforts.

 

	2.	INTERPRETATION

 

	2.1	Defined
    Terms - For the purposes of this Plan, the following terms shall have the following meanings:

 

	 	(a)	“Act”
    means the Securities Act of British Columbia and Alberta where applicable and as amended from time to time;

 

	 	(b)	“Associate”
    shall have the meaning ascribed to such term in the applicable Act;

 

	 	(c)	“Board”
    means the board of directors of the Company;

 

	 	(d)	“Change
    in Control” means:

 

	 	(i)	a
    takeover bid (as defined in the Act), which is successful in acquiring Shares,

 

	 	(ii)	the
    change of control of the Board resulting from the election by the shareholders of the Company of less than a majority of the
    persons nominated for election by management of the Company,

 

	 	(iii)	the
    sale of all or substantially all the assets of the Company,

 

	 	(iv)	the
    sale, exchange or other disposition of a majority of the outstanding Shares in a single transaction or series of related transactions,

 

	 	(v)	the
    dissolution of the Company’s business or the liquidation of its assets,

 

	 	(vi)	a
    merger, amalgamation or arrangement of the Company in a transaction or series of transactions in which the Company’s
    shareholders receive less than 51% of the outstanding shares of the new or continuing corporation, or

 

	 	(vii)	the
    acquisition, directly or indirectly, through one transaction or a series of transactions, by any Person, of an aggregate of
    more than 50% of the outstanding Shares;

 

    	 	 	 

    	I - 2

    

 

	 	(e)	“Committee”
    means a committee of the Board appointed in accordance with this Plan, or if no such committee is appointed, the Board itself;

 

	 	(f)	“Company”
    means BriaCell Therapeutics Corp., a company incorporated under the laws of British Columbia;

 

	 	(g)	“Consultant”
    means an individual, other than an Employee, senior officer or director of the Company or a Subsidiary Company, or a Consultant
    Company, who:

 

	 	(i)	provides
    ongoing bona fide consulting, technical, management or other services to the Company or a Subsidiary Company, other than services
    provided in relation to a distribution of the Company’s securities,

 

	 	(ii)	provides
    the services under a written contract between the Company or a Subsidiary Company and the individual or Consultant Company,

 

	 	(iii)	in
    the reasonable opinion of the Company spends or will spend a significant amount of time and attention on the affairs and business
    of the Company or a Subsidiary Company, and

 

	 	(iv)	has
    a relationship with the Company or a Subsidiary Company that enables the individual or Consultant Company to be knowledgeable
    about the business and affairs of the Company;

 

	 	(h)	“Consultant
    Company” means, for an individual Consultant, a company of which the individual is an employee or shareholder, or
    a partnership of which the individual is an employee or partner;

 

	 	(i)	“Date
    of Grant” means the date specified in the Option Agreement as the date on which the Option is effectively granted;

 

	 	(j)	“Disability”
    means any disability with respect to an Optionee which the Board, in its sole and unfettered discretion, considers likely
    to prevent permanently the Optionee from:

 

	 	(i)	being
    employed or engaged by the Company, a Subsidiary Company or another employer, in a position the same as or similar to that
    in which he was last employed or engaged by the Company or a Subsidiary Company, or

 

	 	(ii)	acting
    as a director or officer of the Company or a Subsidiary Company;

 

	 	(k)	“Disinterested
    Shareholder Approval” means an ordinary resolution approved by a majority of the votes cast by shareholders of the
    Company at a shareholders’ meeting, excluding votes attaching to Shares beneficially owned by Insiders to whom Options
    may be granted and Associates of those persons;

 

	 	(l)	“Effective
Date” means the effective date of this Plan, which is the later of the day of its approval by the shareholders of the
Company and the day of its acceptance for filing by the Exchange if such acceptance for filing is required under the rules or
policies of the Exchange;

 

    	 	 	 

    	I - 3

    

 

	 	(m)	“Eligible
    Person” means:

 

	 	(i)	an
    Employee, senior officer or director of the Company or any Subsidiary Company,

 

	 	(ii)	a
    Consultant,

 

	 	(iii)	an
    individual providing Investor Relations Activities for the Company, or

 

	 	(iv)	a
    company, all of the voting securities of which are beneficially owned by one or more of the persons referred to in (i), (ii)
    or (iii) above.

 

	 	(n)	“Employee”
    means:

 

	 	(i)	an
    individual who is considered an employee under the Income Tax Act (Canada) (i.e. for whom income tax, employment insurance
    and CPP deductions must be made at source),

 

	 	(ii)	an
    individual who works full-time for the Company or a Subsidiary Company providing services normally provided by an employee
    and who is subject to the same control and direction by the Company or a Subsidiary Company over the details and methods of
    work as an employee of the Company or a Subsidiary Company, but for whom income tax deductions are not made at source, or

 

	 	(iii)	an
    individual who works for the Company or a Subsidiary Company, on a continuing and regular basis for a minimum amount of time
    per week, providing services normally provided by an employee and who is subject to the same control and direction by the
    Company or a Subsidiary Company over the details and methods of work as an employee of the Company or a Subsidiary Company,
    but for whom income tax deductions are not made at source;

 

	 	(o)	“Exchange”
    means the stock exchange or over the counter market on which the Shares are listed;

 

	 	(p)	“Fair
    Market Value” means, where the Shares are listed for trading on an Exchange, the last closing price of the Shares
    before the Date of Grant on the Exchange which is the principal trading market for the Shares, as may be determined for such
    purpose by the Committee, provided that, so long as the Shares are listed only on the TSXV, the “Fair Market Value”
    shall not be lower than the last closing price of the Shares before the Date of Grant less the maximum discount permitted
    under the policies of the TSXV;

 

	 	(q)	“Guardian”
    means the guardian, if any, appointed for an Optionee;

 

	 	(r)	“Insider”
    shall have the meaning ascribed to such term in the Act;

 

    	 	 	 

    	I - 4

    

 

	 	(s)	“Investor
    Relations Activities” means any activities or oral or written communications, by or on behalf of the Company or
    a shareholder of the Company that promote or reasonably could be expected to promote the purchase or sale of securities of
    the Company, but does not include:

 

	 	(i)	the
    dissemination of information provided, or records prepared, in the ordinary course of business of the Company:

 

	 	(A)	to
    promote the sale of products or services of the Company, or

 

	 	(B)	to
    raise public awareness of the Company,

 

	 	 	that
    cannot reasonably be considered to promote the purchase or sale of securities of the Company;

 

	 	(ii)	activities
    or communications necessary to comply with the requirements of

 

	 	(A)	applicable
    securities laws, or

 

	 	(B)	the
    rules and policies of the TSXV, if the Shares are listed only on the TSXV, or the by-laws, rules or other regulatory instruments
    of any other self-regulatory body or exchange having jurisdiction over the Company;

 

	 	(iii)	communications
    by a publisher of, or writer for, a newspaper, magazine or business or financial publication, that is of general and regular
    paid circulation, distributed only to subscribers to it for value or to purchasers of it, if:

 

	 	(A)	the
    communication is only through the newspaper, magazine or publication, and

 

	 	(B)	the
    publisher or writer receives no commission or other consideration other than for acting in the capacity of publisher or writer;
    or

 

	 	(iv)	activities
    or communications that may be otherwise specified by the TSXV, if the Shares are listed only on the TSXV;

 

	 	(t)	“Option”
    means an option to purchase unissued Shares granted pursuant to the terms of this Plan;

 

	 	(u)	“Option
    Agreement” means a written agreement between the Company and an Optionee specifying the terms of the Option being
    granted to the Optionee under the Plan;

 

	 	(v)	“Option
    Price” means the exercise price per Share specified in an Option Agreement, adjusted from time to time in accordance
    with the provisions of Sections 6.3 and 10;

 

	 	(w)	“Optionee”
    means an Eligible Person to whom an Option has been granted;

 

	 	(x)	“Person”
    means a natural person, company, government or political subdivision or agency of a government; and where two or more Persons
    act as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of
    securities of an issuer, such syndicate or group shall be deemed to be a Person;

 

	 	(y)	“Plan”
    means this 2014 Stock Option Plan of the Company;

 

    	 	 	 

    	I - 5

    

 

	 	(z)	“Qualified
    Successor” means a person who is entitled to ownership of an Option upon the death of an Optionee, pursuant to a
    will or the applicable laws of descent and distribution upon death;

 

	 	(aa)
    	“Shares”
    means the common shares in the capital of the Company as constituted on the Date of Grant, adjusted from time to time in accordance
    with the provisions of Section 10;

 

	 	(bb)	“Subsidiary
    Company” shall mean a company which is a subsidiary of the Company;
	 	 	 
	 	(cc)	“Term”
    means the period of time during which an Option may be exercised; and

 

	 	(dd)	“TSXV”
    means the TSX Venture Exchange.

 

	3.	ADMINISTRATION

 

	3.1	Board
    or Committee - The Plan shall be administered by the Board or by a Committee appointed in accordance with Section
    3.2.

 

	3.2	Appointment
    of Committee - The Board may at any time appoint a Committee, consisting of not less than three of its members, to
    administer the Plan on behalf of the Board in accordance with such terms and conditions as the Board may prescribe, consistent
    with this Plan. Once appointed, the Committee shall continue to serve until otherwise directed by the Board. From time to
    time, the Board may increase the size of the Committee and appoint additional members, remove members (with or without cause)
    and appoint new members in their place, fill vacancies however caused, or remove all members of the Committee and thereafter
    directly administer the Plan. In the absence of the appointment of a Committee by the Board, the Board shall administer the
    Plan.

 

	3.3	Quorum
    and Voting - A majority of the members of the Committee shall constitute a quorum, and, subject to the limitations
    in this Section 3, all actions of the Committee shall require the affirmative vote of members who constitute a majority of
    such quorum. No member of the Committee who is a director to whom an Option may be granted may participate in the decision
    to grant such Option (but any such member may be counted in determining the existence of a quorum at any meeting of the Committee
    in which action is to be taken with respect to the granting of an Option to him).

 

	3.4	Powers
of Board and Committee - The Board shall from time to time authorize and approve the grant by the Company of Options under
this Plan, and any Committee appointed under Section 3.2 shall have the authority to review the following matters in relation
to the Plan and to make recommendations thereon to the Board:

 

	 	(a)	administration
    of the Plan in accordance with its terms;

 

	 	(b)	determination
    of all questions arising in connection with the administration, interpretation and application of the Plan, including all
    questions relating to the value of the Shares;

 

	 	(c)	correction
    of any defect, supply of any information or reconciliation of any inconsistency in the Plan in such manner and to such extent
    as shall be deemed necessary or advisable to carry out the purposes of the Plan;

 

    	 	 	 

    	I - 6

    

 

		(d)	prescription,
    amendment and rescission of the rules and regulations relating to the administration of the Plan;

 

	 	(e)	determination
    of the duration and purpose of leaves of absence from employment which may be granted to Optionees without constituting a
    termination of employment for purposes of the Plan;

 

	 	(f)	with
    respect to the granting of Options:

 

	 	(i)	determination
    of the employees, officers, directors or consultants to whom Options will be granted, based on the eligibility criteria set
    out in this Plan,

 

	 	(ii)	determination
    of the terms and provisions of the Option Agreement which shall be entered into with each Optionee (which need not be identical
    with the terms of any other Option Agreement) and which shall not be inconsistent with the terms of this Plan,

 

	 	(iii)	amendment
    of the terms and provisions of an Option Agreement, provided the Board obtains:

 

	 	(A)	the
    consent of the Optionee, and

 

	 	(B)	if
    required, the approval of any stock exchange on which the Shares are listed,

 

	 	(iv)	determination
    of when Options will be granted,

 

	 	(v)	determination
    of the number of Shares subject to each Option,

 

	 	(vi)	determination
    of the vesting schedule, if any, for the exercise of each Option; and

 

	 	(g)	other
    determinations necessary or advisable for administration of the Plan.

 

	3.5	Obtain
    Approvals - The Board will seek to obtain any regulatory, Exchange or shareholder approvals which may be required
    pursuant to applicable securities laws or Exchange rules.

 

	3.6	Administration
    by Committee - The Committee shall have all powers necessary or appropriate to accomplish its duties under this Plan.
    In addition, the Committee’s administration of the Plan shall in all respects be consistent with the Exchange policies
    and rules.

 

	4.	ELIGIBILITY

 

	4.1	Eligibility
    for Options - Options may be granted to any Eligible Person.

 

	4.2	Insider
    Eligibility for Options - Notwithstanding Section 4.1, if the Shares are listed only on the TSXV, grants of Options
    to Insiders shall be subject to the policies of the TSXV.

 

	4.3	No
    Violation of Securities Laws - No Option shall be granted to any Optionee unless the Committee has determined that
    the grant of such Option and the exercise thereof by the Optionee will not violate the securities law of the jurisdiction
    in which the Optionee resides.

 

    	 	 	 

    	I - 7

    

 

	5.	SHARES
    SUBJECT TO THE PLAN

 

	5.1	Number
    of Shares – The maximum number of Shares issuable from time to time under the Plan is that number of Shares
    which is equal to 10% of the number of issued Shares of the Company on the Date of Grant of Options. The maximum number of
    Shares issuable under the Plan shall be adjusted, where necessary, to take account of the events referred to in Section 10.

 

	5.2	Expire
    of Option - If an Option expires or terminates for any reason without having been exercised in full, the unpurchased
    Shares subject thereto shall again be available for the purposes of the Plan.

 

	5.3	Reservation
    of Shares - The Company will at all times reserve for issuance and keep available such number of Shares as shall be
    sufficient to satisfy the requirements of the Plan.

 

	6.	OPTION
    TERMS

 

	6.1	Option
    Agreement - Each Option granted to an Optionee shall be confirmed by the execution and delivery of an Option Agreement
    and the Board shall specify the following terms in each such Option Agreement:

 

	 	(a)	the
    number of Shares subject to option pursuant to such Option, subject to the following limitations if the Shares are listed
    only on the TSXV:

 

	 	(i)	the
    number of Shares reserved for issuance pursuant to Options to any one Optionee shall not exceed 5% of the issued Shares in
    any 12-month period (unless the Company is designated as a “Tier 1” listed company by the TSXV and has obtained
    Disinterested Shareholder Approval to exceed this number),

 

	 	(ii)	the
    number of Shares reserved for issuance pursuant to Options to any one Consultant shall not exceed 2% of the issued Shares
    in any 12-month period, and

 

	 	(iii)	the
    aggregate number of Shares reserved for issuance pursuant to Options to Employees and those individuals conducting Investor
    Relations Activities shall not exceed 2% of the issued Shares in any 12-month period;

 

	 	(b)	the
    Date of Grant;

 

	 	(c)	the
    Term, provided that, if the Shares are listed only on the TSXV, the length of the Term shall in no event be greater than five
    years following the Date of Grant, except, if the Company is designated as “Tier 1” listed company by the TSXV,
    then the Term shall be no greater than ten years following the Date of Grant, for all Optionees;

 

	 	(d)	the
    Option Price, provided that the Option Price shall not be less than the Fair Market Value of the Shares on the Date of Grant;

 

	 	(e)	subject
    to Section 6.2 below, any vesting schedule upon which the exercise of an Option is contingent;

 

	 	(f)	if
    the Optionee is an Employee, Consultant or an individual providing Investor Relations Activities for the Company, a representation
    by the Company and the Optionee that the Optionee is a bona fide Employee, Consultant or an individual providing Investor
    Relations Activities for the Company, as the case may be, of the Company or a Subsidiary Company; and

 

	 	(g)	such
    other terms and conditions as the Board deems advisable and are consistent with the purposes of this Plan.

 

    	 	 	 

    	I - 8

    

 

	6.2	Vesting
    Schedule - The Board, as applicable, shall have complete discretion to set the terms of any vesting schedule of each
    Option granted, including, without limitation, discretion to:

 

	 	(a)	permit
    partial vesting in stated percentage amounts based on the Term of such Option;

 

	 	(b)	permit
    full vesting after a stated period of time has passed from the Date of Grant; and

 

	 	(c)	any
    options issued to Consultants performing Investor Relations Activities must vest in stages over 12 months with no more than
    1⁄4 of the options vesting in any three month period.

 

	6.3	Amendments
    to Options - Amendments to the terms of previously granted Options are subject to regulatory approval, if required.
    If required by the Exchange, Disinterested Shareholder Approval shall be required for any reduction in the Option Price of
    a previously granted Option if the Optionee is an Insider of the Company at the time of the proposed reduction in the Option
    Price.

 

	6.4	Uniformity
    - Except as expressly provided herein, nothing contained in this Plan shall require that the terms and conditions
    of Options granted under the Plan be uniform.

 

	7.	EXERCISE
    OF OPTION

 

	7.1	Method
    of Exercise - Subject to any limitations or conditions imposed upon an Optionee pursuant to the Option Agreement or
    Section 6 hereof, an Optionee may exercise an Option by giving written notice thereof, specifying the number of Shares in
    respect of which the Option is exercised, to the Company at its principal place of business at any time after the Date of
    Grant until 4:00 p.m. (Vancouver time) on the last day of the Term, such notice to be accompanied by full payment of the aggregate
    Option Price to the extent the Option is so exercised. Such payment shall be in lawful money (Canadian funds) by cash, cheque,
    bank draft or wire transfer. Payment by cheque made payable to the Company in the amount of the aggregate Option Price shall
    constitute payment of such Option Price unless the cheque is not honoured upon presentation, in which case the Option shall
    not have been validly exercised.

 

	7.2	Issuance
    of Certificates - Not later than the third business day after exercise of an Option in accordance with Section 7.1,
    the Company shall issue and deliver to the Optionee a certificate or certificates evidencing the Shares with respect to which
    the Option has been exercised. Until the issuance of such certificate or certificates, no right to vote or receive dividends
    or any other rights as a shareholder shall exist with respect to such Shares, notwithstanding the exercise of the Option.
    No adjustment will be made for a dividend or other right for which the record date is prior to the date the certificate is
    issued, except as provided by Section 10 hereof.

 

    	 	 	 

    	I - 9

    

 

	7.3	Compliance
    with U.S. Securities Laws - As a condition to the exercise of an Option, the Board may require the Optionee to represent
    and warrant in writing at the time of such exercise that the Shares are being purchased only for investment and without any
    then-present intention to sell or distribute such Shares. At the option of the Board, a stop transfer order against such Shares
    may be placed on the stock books and records of the Company and a legend, indicating that the stock may not be pledged, sold
    or otherwise transferred unless an opinion of counsel is provided stating that such transfer is not in violation of any applicable
    law or regulation, may be stamped on the certificates representing such Shares in order to assure an exemption from registration.
    The Board may also require such other documentation as may from time to time be necessary to comply with United States federal
    and state securities laws. The Company has no obligation to undertake registration of Options or the Shares issuable upon
    the exercise of the Options.

 

	8.	TRANSFERABILITY
    OF OPTIONS

 

	8.1	Non-Transferable/Legending -
    Except as permitted by applicable securities laws and the policies of the Exchange, and as provided otherwise in     this
    Section 8, Options are non-assignable and non-transferable. If the Shares are listed only on the TSXV, then, in addition
    to any resale restrictions under applicable securities laws, if the Company is, at the Date of Grant of an Option,
    designated     as a “Tier 2” listed company by the TSXV or, if the Company is not so designated but the Option
    Price is based     on a discount from the last closing price of the Shares on the TSXV, the Option Agreement and the
    certificates representing     the Shares issued on the exercise of such Option shall bear the TSXV legend with a four-month
    hold period commencing on the     Date of Grant if required under TSXV Policies.

 

	8.2	Death
    of Optionee - Subject to Section 8.3, if the employment of an Optionee as an Employee of, or the services of a Consultant
    providing services to, the Company or any Subsidiary Company, or the employment of an Optionee as an individual providing
    Investor Relations Activities, or the position of the Optionee as a director or senior officer of the Company or any Subsidiary
    Company, terminates as a result of such Optionee’s death, any Options held by such Optionee shall pass to the Qualified
    Successor of the Optionee and shall be exercisable by such Qualified Successor until the earlier of a period of not more than
    one year following the date of such death and the expiry of the Term of the Option.

 

	8.3	Disability
    of Optionee - If the employment of an Optionee as an Employee of, or the services of a Consultant providing services
    to, the Company or any Subsidiary Company, or the employment of an Optionee as an individual providing Investor Relations
    Activities for the Company, or the position of the Optionee as a director or senior officer of the Company or any Subsidiary
    Company, is terminated by reason of such Optionee’s Disability, any Options held by such Optionee that could have been
    exercised immediately prior to such termination of employment or service shall be exercisable by such Optionee, or by his
    Guardian, for a period of 30 days following the termination of employment or service of such Optionee. If such Optionee dies
    within that 30-day period, any Option held by such Optionee that could have been exercised immediately prior to his or her
    death shall pass to the Qualified Successor of such Optionee, and shall be exercisable by the Qualified Successor until the
    earlier of a period of 30 days following the death of such Optionee and the expiry of the Term of the Option.

 

	8.4	Vesting - Options held by a Qualified Successor or exercisable by a Guardian shall, during the period prior to their termination,
    continue to vest in accordance with any vesting schedule to which such Options are subject.

 

	8.5	Deemed
    Non-Interruption of Employment - Employment shall be deemed to continue intact during any military or sick leave or
    other bona fide leave of absence if the period of such leave does not exceed 90 days or, if longer, for so long as the Optionee’s
    right to reemployment with the Company or any Subsidiary Company is guaranteed either by statute or by contract. If the period
    of such leave exceeds 90 days and the Optionee’s reemployment is not so guaranteed, then the Optionee’s employment
    shall be deemed to have terminated on the ninety-first day of such leave.

 

    	 	 	 

    	I - 10

    

 

	9.	TERMINATION
    OF OPTIONS

 

	9.1	Termination
    of Options - To the extent not earlier exercised or terminated in accordance with Section 8, an Option shall terminate
    at the earliest of the following dates:

 

	 	(a)	the
    termination date specified for such Option in the Option Agreement;

 

	 	(b)	where
    the Optionee’s position as an Employee, a Consultant, a director or a senior officer of the Company or any Subsidiary
    Company, or an individual providing Investor Relations Activities for the Company, is terminated for cause, the date of such
    termination for cause;

 

	 	(c)	where
    the Optionee’s position as an Employee, a Consultant, a director or a senior officer of the Company or any Subsidiary
    Company or an individual providing Investor Relations Activities for the Company terminates for a reason other than the Optionee’s
    Disability or death or for cause, not more than 90 days after such date of termination or, if the Shares are listed only on
    the TSXV and if the Company is designated as a “Tier 2” listed company by the TSXV, then in the case of a person
    employed to provide Investor Relations Activities, not more than 30 days after such person ceases to be employed to provide
    Investor Relations Activities; PROVIDED that if an Optionee’s position changes from one of the said categories to another
    category, such change shall not constitute termination or cessation for the purpose of this Subsection 9.1(c); and

 

	 	(d)	the
    date of any sale, transfer, assignment or hypothecation, or any attempted sale, transfer, assignment or hypothecation, of
    such Option in violation of Section 8.1.

 

	9.2	Lapsed
    Options - If Options are surrendered, terminate or expire without being exercised in whole or in part, new Options
    may be granted covering the Shares not purchased under such lapsed Options. If an Option has been surrendered in connection
    with the regranting of a new Option to the same Optionee on different terms than the original Option granted to such Optionee,
    then, if required, the new Option is subject to approval of the Exchange.

 

	9.3	Exclusion
    From Severance Allowance, Retirement Allowance or Termination Settlement - If the Optionee retires, resigns or is
    terminated from employment or engagement with the Company or any Subsidiary Company, the loss or limitation, if any, pursuant
    to the Option Agreement with respect to the right to purchase Option Shares which were not vested at that time or which, if
    vested, were cancelled, shall not give rise to any right to damages and shall not be included in the calculation of nor form
    any part of any severance allowance, retiring allowance or termination settlement of any kind whatsoever in respect of such
    Optionee.

 

	10.	ADJUSTMENTS
    TO OPTIONS

 

	10.1	Alteration
    in Capital Structure - If there is any change in the Shares through or by means of a declaration of stock dividends
    of the Shares or consolidations, subdivisions or reclassifications of the Shares, or otherwise, the number of Shares available
    under the Plan, the Shares subject to any Option and the Option Price therefor shall be adjusted proportionately by the Board
    and, if required, approved by the Exchange, and such adjustment shall be effective and binding for all purposes of the Plan.

 

    	 	 	 

    	I - 11

    

 

	10.2	Effect
    of Amalgamation, Merger or Arrangement - If the Company amalgamates, merges or enters into a plan of arrangement with
    or into another corporation, any Shares receivable on the exercise of an Option shall be converted into the securities, property
    or cash which the Optionee would have received upon such amalgamation, merger or arrangement if the Optionee had exercised
    the Option immediately prior to the record date applicable to such amalgamation, merger or arrangement, and the exercise price
    shall be adjusted proportionately by the Board and such adjustment shall be binding for all purposes of the Plan.

 

	10.3	Acceleration
    on Change in Control - Upon a Change in Control, all Options shall become immediately exercisable, notwithstanding
    any contingent vesting provisions to which such Options may have otherwise been subject.

 

	10.4	Acceleration
    of Date of Exercise - Subject to the approval of the Exchange, if required, the Board shall have the right to accelerate
    the date of vesting of any portion of any Option which remains unvested.

 

	10.5	Determinations
    to be Binding - If any questions arise at any time with respect to the Option Price or exercise price or number of
    Option Shares or other property deliverable upon exercise of an Option following an event referred to in this Section 10,
    such questions shall be conclusively determined by the Board, whose decisions shall be final and binding.

 

	10.6	Effect
    of a Take-Over - If a bona fide offer (the “Offer”) for Shares is made to an Optionee or
    to shareholders generally or to a class of shareholders which includes the Optionee, which Offer constitutes a take-over bid
    within the meaning of the Act, the Company shall, immediately upon receipt of notice of the Offer, notify each Optionee of
    full particulars of the Offer, whereupon any Option held by an Optionee may be exercised in whole or in part, notwithstanding
    any contingent vesting provisions to which such Options may have otherwise been subject, by the Optionee so as to permit the
    Optionee to tender the Shares received upon such exercise (the “Optioned Shares”) to the Offer. If:

 

	 	(a)	the
    Offer is not completed within the time specified therein; or

 

	 	(b)	all
        of the Optioned Shares tendered by the Optionee pursuant to the Offer are not taken up and paid for by the offeror pursuant
        thereto; the Optioned Shares or, in the case of clause (b) above, the Optioned Shares that are not taken up and paid for,
        may be returned by the Optionee to the Company and reinstated as authorized but unissued Shares and with respect to such
        returned Optioned Shares, the Option shall be reinstated as if it had not been exercised. If any Optioned Shares are returned
        to the Company under this Section, the Company shall refund to the Optionee any Option Price paid for such Optioned Shares.

         

 

	11.	APPROVAL,
    TERMINATION AND AMENDMENT OF PLAN

 

	11.1	Shareholder
    Approval - This Plan, if the Shares are listed only on the TSXV, is subject to:

 

	 	(a)	shareholder
    approval on a yearly basis at the Company’s next ensuing annual general meeting; and

 

    	 	 	 

    	I - 12

    

 

	 	(b)	Disinterested
    Shareholder Approval if:

 

	 	(i)	a
    stock option plan, together with all of the Issuer’s previously established and outstanding stock option plans or grants,
    could result at any time in:

 

	 	(A)	the
    number of shares reserved for issuance under stock options granted to Insiders exceeding 10% of the issued shares,

 

	 	(B)	the
    grant to Insiders, within a 12 month period, of a number of options exceeding 10% of the issued share, or

 

	 	(C)	the
    issuance to any one Optionee, within a 12 month period, of a number of shares exceeding 5% of the issued share, or

 

	 	(ii)	the
    Issuer is decreasing the exercise price of stock options previously granted to Insiders.

 

	11.2	Power
    of Board to Terminate or Amend Plan - Subject to the approval of the Exchange, if required, the Board may terminate,
    suspend or discontinue the Plan at any time or amend or revise the terms of the Plan; provided, however, that, except as provided
    in Section 10, the Board may not do any of the following without obtaining, within 12 months either before or after the Board’s
    adoption of a resolution authorizing such action, approval by the Company’s shareholders at a meeting duly held in accordance
    with the applicable corporate laws:

 

	 	(a)	increase
    the maximum number of Shares which may be issued under the Plan;

 

	 	(b)	materially
    modify the requirements as to eligibility for participation in the Plan; or

 

	 	(c)	materially
    increase the benefits accruing to participants under the Plan;

 

	 	however,
                                         the Board may amend the terms of the Plan to comply with the requirements of any applicable
                                         regulatory authority, or as a result of changes in the policies of the Exchange relating
                                         to director, officer and employee stock options, without obtaining the approval of the
                                         Company’s shareholders.

        

 

	11.3	No
    Grant During Suspension of Plan - No Option may be granted during any suspension, or after termination, of the Plan.
    Amendment, suspension or termination of the Plan shall not, without the consent of the Optionee, alter or impair any rights
    or obligations under any Option previously granted.

 

	12.	CONDITIONS
    PRECEDENT TO ISSUANCE OF SHARES

 

	12.1	Compliance
    with Laws - Shares shall not be issued with respect to an Option unless the exercise of such Option and the issuance
    and delivery of such shares shall comply with all relevant provisions of law, including, without limitation, any applicable
    United States state securities laws, the Securities Act of 1933, as amended, the rules and regulations thereunder and
    the requirements of any Exchange or automated interdealer quotation system of a registered national securities association
    upon which such Shares may then be listed or quoted, and such issuance shall be further subject to the approval of counsel
    for the Company with respect to such compliance, including the availability of an exemption from registration for the issuance
    and sale of such Shares. The inability of the Company to obtain from any regulatory body the authority deemed by the Company
    to be necessary for the lawful issuance and sale of any Shares under this Plan, or the unavailability of an exemption from
    registration for the issuance and sale of any Shares under this Plan, shall relieve the Company of any liability with respect
    to the non-issuance or sale of such Shares other than with respect to a refund of any Option Price paid.

 

    	 	 	 

    	I - 13

    

 

	13.	USE
    OF PROCEEDS

 

	13.1	Use
    of Proceeds - Proceeds from the sale of Shares pursuant to the Options granted and exercised under the Plan shall
    constitute general funds of the Company and shall be used for general corporate purposes, or as the Board otherwise determines.

 

	14.	NOTICES

 

	14.1	Notices - All notices, requests, demands and other communications required or permitted to be given under this Plan and the
    Options granted under this Plan shall be in writing and shall be either delivered personally to the party to whom notice is
    to be given, in which case notice shall be deemed to have been duly given on the date of such personal delivery; telecopied,
    in which case notice shall be deemed to have been duly given on the date the telecopy is sent; or mailed to the party to whom
    notice is to be given, by first class mail, registered or certified, return receipt requested, postage prepaid, and addressed
    to the party at his or its most recent known address, in which case such notice shall be deemed to have been duly given on
    the tenth postal delivery day following the date of such mailing.

 

	15.	MISCELLANEOUS
    PROVISIONS

 

	15.1	No
    Obligations to Exercise - Optionees shall be under no obligation to exercise Options granted under this Plan.

 

	15.2	No
    Obligation to Retain Optionee - Nothing contained in this Plan shall obligate the Company or any Subsidiary Company
    to retain an Optionee as an employee, officer, director or consultant for any period, nor shall this Plan interfere in any
    way with the right of the Company or any Subsidiary Company to reduce such Optionee’s compensation.

 

	15.3	Binding
    Agreement - The provisions of this Plan and of each Option Agreement with an Optionee shall be binding upon such Optionee
    and the Qualified Successor or Guardian of such Optionee.

 

	15.4	Use
    of Terms - Where the context so requires, references herein to the singular shall include the plural, and vice versa,
    and references to a particular gender shall include either or both genders.

 

	15.5	Headings - The headings used in this Plan are for convenience of reference only and shall not in any way affect or be used
    in interpreting any of the provisions of this Plan.

 

	15.6	No
    Representation or Warranty - The Company makes no representation or warranty as to the future value of any Shares
    issued in accordance with the provisions of this Plan.

 

	15.7	Income
    Taxes - As a condition of and prior to participation in the Plan any Optionee shall on request authorize the Company
    in writing to withhold from any remuneration otherwise payable to such Optionee any amounts required by any taxing authority
    to be withheld for taxes of any kind as a consequence of such Optionee’s participation in the Plan.

 

    	 	 	 

    	I - 14

    

 

	15.8	Withholding
    Tax Requirements - Upon exercise of an Option, the Optionee will, upon notification of the amount due and prior to
    or concurrently with the delivery of the certificates representing the Common Shares, pay to the Company amounts necessary
    to satisfy applicable withholding tax requirements or will otherwise make arrangements satisfactory to the Company for such
    requirements. In order to implement this provision, the Company or any related corporation will have the right to retain and
    withhold from any payment of cash or Common Shares under this Plan the amount of taxes required to be withheld or otherwise
    deducted and paid in respect of such payment. At its discretion, the Company may require the Optionee receiving Common Shares
    to reimburse the Company for any such taxes required to be withheld by the Company and withhold any distribution to the Optionee
    in whole or in part until the Company is so reimbursed. In lieu thereof, the Company will have the right to withhold from
    any cash amount due or to become due from the Company to the Optionee an amount equal to such taxes. The Company may also
    retain and withhold or the Optionee may elect, subject to approval by the Company at its sole discretion, to have the Company
    retain and withhold a number of Common Shares having a market value not less than the amount of such taxes required to be
    withheld by the Company to reimburse the Company for any such taxes and cancel (in whole or in part) any such Common Shares
    so withheld.

 

	15.9	Compliance with Applicable Law - If any provision of the Plan or any Option Agreement contravenes any law or any order, policy,
    by-law or regulation of any regulatory body or stock exchange or over the counter market having authority over the Company
    or the Plan, then such provision shall be deemed to be amended to the extent required to bring such provision into compliance
    therewith.

 

	15.10	Conflict - In the event of any conflict between the provisions of this Plan and an Option Agreement, the provisions of this
    Plan shall govern.

 

	15.11	Governing
    Law - This Plan and each Option Agreement issued pursuant to this Plan shall be governed by the laws of the Province
    of Ontario.

 

	15.12	Time
    of Essence - Time is of the essence of this Plan and of each Option Agreement. No extension of time will be deemed
    to be, or to operate as, a waiver of the essentiality of time.

 

	15.13	Entire
    Agreement - This Plan and the Option Agreement sets out the entire agreement between the Company and the Optionees
    relative to the subject matter hereof and supersedes all prior stock option plans, agreements, undertakings and understandings,
    whether oral or written.

 

	16.	EFFECTIVE
    DATE OF PLAN

 

	16.1	Effective
    Date of Plan - This Plan shall be effective on the later of the day of its approval by the shareholders of the Company
    given by way of ordinary resolution and the day of its acceptance for filing by the Exchange.AGREEMENT
FOR SERVICES

 

This
Agreement for Services (“Agreement”) is made by and between The Regents of the University of California, a California
constitutional corporation, acting for and on behalf of its University of California, Davis Health System (“UNIVERSITY”),
and Briacell Therapeutics Corp., a private California corporation, (“COMPANY”). UNIVERSITY and COMPANY are referred
to individually as a “Party” and collectively as the “Parties”.

 

WHEREAS,
COMPANY desires that UNIVERSITY’s Institute of Regenerative Cures provide GMP Facility services for the purpose of manufacturing
cell-based vaccine (BriaVax XV-BR-1-GM) and control cell line;

 

WHEREAS,
UNIVERSITY is fully qualified and desires to provide such services to COMPANY;

 

WHEREAS,
UNIVERSITY has determined that the provision of such services shall not adversely affect the conduct of UNIVERSITY activities;
and

 

WHEREAS,
UNIVERSITY has determined that furnishing of services requested by COMPANY is consistent with one or more of UNIVERSITY’s
missions.

 

THEREFORE,
the Parties agree to the terms and conditions contained herein.

 

TERMS
AND CONDITIONS

 

	1.	SCOPE
    OF SERVICES

 

During
the term of this Agreement, UNIVERSITY shall render services in accordance with the Scope of Services attached hereto as Exhibit
A and incorporated herein (“Services”).

 

	2.	TERM

 

The
term of this Agreement shall commence on June 10, 2015 (the “Effective Date”) and shall continue for a period
of one (1) year, unless earlier terminated. This Agreement may be extended by mutual agreement of the Parties.

 

	3.	TERMINATION

 

Either
Party may terminate this Agreement without cause by giving thirty (30) calendar days written notice to the other. To effect termination
in the event of a material breach of this Agreement, the aggrieved party must provide written notice of the breach to the offending
party and allow the offending party ten (10) business days to cure the breach. If the offending party does not cure the breach
within ten (10) business days, the Agreement will immediately and automatically terminate on the eleventh (11th)
day. This Agreement shall be subject to immediate termination in the event that any Party is excluded from participation
in any federal healthcare or procurement program. Termination or expiration of this Agreement shall not affect any rights or obligations
of the Parties that accrued prior to the date of termination.

 

    	Page 1 of 11

    	 

    

 

	4.	COMPENSATION

 

	 	A.	COMPANY
    shall pay UNIVERSITY for Services provided in accordance with the compensation terms in Exhibit A.

 

	 	B.	COMPANY
    shall pay such compensation within thirty (30) calendar days of receipt of an invoice setting forth the project number for
    the Services performed and the Agreement number corresponding with the Services. Such payment shall be made by check payable
    to The Regents of the University of California and sent to the address indicated on the invoice. COMPANY shall also reimburse
    UNIVERSITY for all necessary and reasonable business expense incurred by UNIVERSITY pursuant to UNIVERSITY’s duties
    under this Agreement, provided that such expenses have been approved in advance by COMPANY and are properly itemized and documented.

 

	 	C.	COMPANY
    shall pay UNIVERSITY for all Services rendered and obligations incurred under the Agreement that cannot reasonably be terminated
    immediately upon notice of termination up to the date of termination of this Agreement, regardless of the reason for termination.

 

	5.	CONFIDENTIALITY
    OF INFORMATION

 

During
the term of this Agreement and for a period of three (3) years after termination or expiration hereof, UNIVERSITY shall use its
reasonable efforts, consistent with its established policies and procedures, to protect the confidentiality of any information
furnished to it by COMPANY in connection with this Agreement and expressly designated by COMPANY, in writing, as confidential.
Upon completion or termination of this Agreement UNIVERSITY shall, upon request, destroy or return to COMPANY all such confidential
materials.

 

UNIVERSITY
shall have no obligation to protect the confidentiality of any information that: (a) is in the public domain through no fault
of UNIVERSITY; (b) is received by UNIVERSITY from a third party under no obligation of confidentiality to COMPANY; (c) is required
by law to be disclosed; (d) was known by UNIVERSITY prior to the time of first disclosure by COMPANY; or (e) is independently
developed by UNIVERSITY.

 

    	Page 2 of 11

    	 

    

 

	6.	UNIVERSITY’S
    RIGHT TO USE DATA

 

UNIVERSITY
shall have the unrestricted right to use for its own purposes, including publication, any data or information it may develop in
connection with or as a result of performing the Services described in Exhibit A. UNIVERSITY agrees to submit a copy of intended
publication materials to COMPANY for review and comment at least sixty (60) calendar days prior to submission for publication;
provided, however, that COMPANY shall have no editorial rights over publication materials but may request, and UNIVERSITY will
agree to, an additional delay of up to thirty (30) calendar days to allow for filing of regulatory documents or to secure patent
protection on patentable subject matter resulting from this Agreement.

 

	7.	USE
    OF UNIVERSITY’S NAME

 

COMPANY
shall not use the name or logos of the UNIVERSITY, including but not limited to The Regents of the University of California, University
of California or UC Davis, in any form or manner in any publicity, advertisements, reports or other information released to the
public without UNIVERSITY’s prior written approval. California Education Code Section 92000 prohibits use of University’s
name(s) to suggest that UNIVERSITY endorses a product or service.

 

	8.	INDEMNIFICATION

 

The
Parties agree to defend, indemnify and hold one another harmless from and against any and all liability, loss, expense, attorneys’
fees, or claims for injury or damages arising from the performance of this Agreement, but only in proportion to and to the extent
such liability, loss, expense, attorneys’ fees, or claims for injury or damages are caused by or result from the negligent
or intentional acts or omissions of the indemnifying Party, its officers, agents or employees.

 

	9.	INSURANCE

 

Each
Party, at its sole cost and expense, shall insure its activities in connection with this Agreement and obtain, keep in force and
maintain insurance or self-insure during the term hereof as follows:

 

	 	A.	General
    Liability:

 

Comprehensive
or Commercial Form (MINIMUM LIMITS)

 

	(1	)	Each
    Occurrence	 	$	1,000,000	 
	(2	)	Products
    Completed Operations Aggregate	 	$	2,000,000	*
	(3	)	Personal
    and Advertising Injury	 	$	1,000,000	 
	(4	)	General
    Aggregate	 	$	2,000,000	*

 

*
($1,000,000 for comprehensive form)

 

    	Page 3 of 11

    	 

    

 

However,
if such insurance is written on a claims-made form, following termination of the Agreement, coverage shall survive for a period
of not less than three (3) years. Coverage shall provide for a retroactive date of placement prior to or coinciding with the Effective
Date of the Agreement. 

 

	 	B.	Workers’
    compensation insurance as required under applicable state law.

 

	 	C.	The
    limits and coverages required herein shall in no way limit the liability of the Parties, including the Parties’ indemnification
    obligations herein.

 

	 	D.	Upon
    request, each Party shall supply to the other a certificate, or certificates, of insurance/self-insurance evidencing coverage
    in the amounts and for the perils listed above.

 

	10.	DISCLAIMER
    OF WARRANTY

 

UNIVERSITY
MAKES NO WARRANTY AS TO RESULTS TO BE OBTAINED BY COMPANY FROM THE USE OF ANY SERVICES PROVIDED BY UNIVERSITY UNDER THIS AGREEMENT,
AND EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES INCLUDING, BUT NOT LIMITED TO, THE WARRANTIES OF MERCHANTABILITY AND FITNESS
FOR A PARTICULAR PURPOSE.

 

	11.	NON-LIABILITY
    OF UNIVERSITY

 

UNIVERSITY
shall not be liable, by reason of its performance under this Agreement, for any loss of profits, claims against COMPANY by any
third party, or consequential damages even if UNIVERSITY is advised of the possibility of such loss, claims, or damages. COMPANY
agrees that UNIVERSITY’s liability hereunder for damages, regardless of the form of action, shall not exceed the total of
all charges actually paid by COMPANY for the particular Services rendered.

 

	12.	RELATIONSHIP
    OF THE PARTIES

 

The
Parties to this Agreement shall be and remain at all times independent contractors, neither being the employee, agent, representative,
or sponsor of the other in their relationship under this Agreement.

 

	13.	NO
    REQUIREMENT FOR REFERRALS

 

Nothing
in this Agreement or in any other related written or oral agreement requires the admission or referral of patients or business
by any Party to the other. This Agreement and the remuneration provided are not intended to influence the decision of any Party
in choosing the hospital, health care facility or other provider/supplier of health care goods and services deemed by such Party
as the best qualified to deliver goods or services, and the rights of any Party under this Agreement shall not depend in any way
on the referral of patients or business to the other.

 

    	Page 4 of 11

    	 

    

 

	14.	EXCLUSION

 

Each
Party represents that neither it nor its employees or agents providing services under this Agreement is excluded from participation
in any governmental sponsored program, including, without limitation, the Medicare, Medicaid, or TRICARE programs (http://exclusions.oig.hhs.gov/search.htm1)
and the Federal Procurement and Nonprocurement Programs (https://www.sam.gov).

 

	15.	FAIR
    MARKET VALUE

 

The
Parties acknowledge that the compensation set forth herein represents the fair market value of the Services provided by UNIVERSITY,
was negotiated in an arms-length transaction and has not been determined in a manner that takes into account the volume or value
of any referrals or business otherwise generated between COMPANY and UNIVERSITY. The Parties further agree that this Agreement
does not involve the counseling or promotion of a business arrangement that violates state or federal law. Nothing contained herein
shall be construed in any manner as an obligation or inducement for UNIVERSITY to recommend that any person or entity purchase
COMPANY products or those of any organization affiliated with COMPANY.

 

	16.	APPLICABLE
    LAW

 

The
Parties to this Agreement specifically intend to comply with all applicable laws, rules, and regulations, including the federal
anti-kickback statute (42 USC Section 1320a-7b) and the related safe harbor regulations.

 

	17.	NON-DISCRIMINATION

 

Both
Parties agree not to discriminate in their performance under this Agreement on the basis of race, color, national origin, religion,
sex, sexual orientation, disability, age, veterans’ status, medical condition (cancer-related) as defined in section 12926
of the California Government Code, ancestry, marital status or citizenship.

 

	18.	ALTERATION,
    AMENDMENT

 

This
Agreement may be amended at any time by agreement of the Parties, expressed in writing and signed by both Parties. No alteration
of the terms of this Agreement shall be valid or binding upon either Party unless made in writing and signed by both Parties,
and no other terms and conditions, including, but not limited to, those of any purchase order issued by COMPANY, shall apply unless
explicitly incorporated herein.

 

    	Page 5 of 11

    	 

    

 

	19.	HEADINGS

 

The
section headings used in this Agreement are inserted for convenience only, are not substantive, and shall not be used to limit,
define, describe, or otherwise interpret any provision of this Agreement.

 

	20.	COUNTERPARTS

 

This
Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which constitute one instrument.
In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data
file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or “.pdf” signature page was an original thereof.

 

	21.	NOTICE

 

All
notices, requests, or other communications required or anticipated under this Agreement shall be in writing and shall be delivered
to the respective Parties by personal delivery; by United States Postal Service as certified or registered mail, postage prepaid,
return receipt requested; or by a reputable overnight delivery service such as Federal Express, addressed to the respective Parties
at the addresses set forth below. Notices shall be deemed delivered on the date of personal delivery, two days following the date
indicated on the United States Postal Service return receipt, or one day following deposit with overnight delivery service.

 

		To
    UNIVERSITY:	University
                                         of California Davis Health System

        Health
        System Contracts

        Sherman Building, Suite 2300

        2315 Stockton Boulevard

        Sacramento, CA 95817

        (Reference University Agreement No. S15-00193V)

	 	 	 
	 	To
    COMPANY:	Briacell
    Therapeutics Corp.
	 	 	8900
    Wilshire Boulevard, Suite 310 

    Beverly Hills, CA 90211

 

	22.	GOVERNING
    LAW

 

This
Agreement shall be construed in accordance with the laws of the State of California.

 

	23.	ASSIGNMENT

 

No
Party to this Agreement may assign this Agreement, assign rights or delegate duties hereunder without the prior written consent
of the other Party hereto. Except as specifically provided in this Agreement, any attempted assignment or delegation of a Party’s
rights, claims, privileges, duties or obligations hereunder shall be null and void.

 

    	Page 6 of 11

    	 

    

 

	24.	FORCE
    MAJEURE

 

If
either Party’s performance of this Agreement is prevented, restricted or delayed, either totally or in part, for reasons
beyond the affected Party’s reasonable control and is not due to the action or inaction of such Party, the affected Party
will, upon giving notice to the other Party, be excused from such performance to the extent of such prevention, restriction or
delay; provided, that the affected Party will use reasonable efforts to avoid or remove such causes of non- performance and will
continue its performance whenever such causes are removed. For purposes of this Section, a lack of funds shall not be considered
a cause beyond the reasonable control of the Parties.

 

	25.	SEVERABILITY

 

If
any section or part of this Agreement is held to be void, invalid or unenforceable by order, decree or judgment of a court of
competent jurisdiction, the remainder of the Agreement shall remain in full force and effect, and the Parties agree to negotiate
in good faith to agree upon replacement language that expresses the Parties’ intent in a manner that is valid and enforceable.

 

	26.	REMEDIES
    AND WAIVER

 

The
remedies provided in this Agreement are not exclusive and the Party suffering from a breach or default of this Agreement may pursue
all available remedies, both legal and equitable. No express or implied waiver by a Party of any breach or default will be construed
as a waiver of a future or subsequent breach or default. The failure or delay of any Party in exercising any of its rights under
this Agreement will not constitute a waiver of any such right, and any single or partial exercise of any particular right by any
Party will not exhaust the same or constitute a waiver of any other right provided in this Agreement.

 

	27.	ATTORNEY’S
    FEES

 

If
any action at law or equity is brought to enforce the terms of this Agreement, including collection of delinquent payment, the
prevailing Party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other
relief to which it may be entitled.

 

	28.	NO
    THIRD PARTY BENEFICIARIES

 

The
Parties do not intend the benefits of this Agreement to inure to or benefit any third person or entity not a Party hereto.

 

    	Page 7 of 11

    	 

    

 

	29.	SURVIVAL

 

Any
obligations and duties that by their nature are intended to extend beyond the expiration or earlier termination of this Agreement
shall survive termination or expiration of this Agreement and remain in full force and effect as necessary or appropriate.

 

	30.	ENTIRE
    AGREEMENT

 

This
Agreement constitutes the entire understanding of the Parties respecting the subject matter hereof and supersedes any prior understanding
or agreement between them, written or oral, regarding the same subject matter. If there is any conflict between the terms of this
Agreement and the language in any of the attachments hereto, the terms of this Agreement shall control.

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement on the day and year last signed below.

 

	THE
    REGENTS OF THE UNIVERSITY OF CALIFORNIA	 	BRIACELL
    THERAPEUTICS CORP.
	 	 	 	 	 
	By	 	 	By	
	 	Annie
    Wong, Director 	 	Name	JOSEPH
    WAGNER
	 	UC
    Davis Health System Contracts	 	Title	PRESIDENT
    and CEO
	 	 	 	 	 
	Date	 	 	Date	11
    JUNE 2015

 

    	Page 8 of 11

    	 

    

  

EXHIBIT
A

SCOPE
OF WORK AND BUDGET

(Dated
May 14, 2015)

 

I.
SCOPE OF WORK

 

A.
UNIVERSITY GMP manufacturing of a cell-based vaccine (BriaVax SV-BR-1-GM) and a control cell line
(“Services”) scope of work and cost estimates given to COMPANY’s employee:

 

Dr.
Charles L. Wiseman

Chairman and CEO

Briacell Therapeutics Corp.

8900 Wilshire Blvd. Suite 310

Beverly Hills, CA 90211

Mobile: 323-377-4741

Email:
cw@briacell.com

 

	B.	Work
    associated with the Services:

 

Transfer
of technology and procedures from BriaCell to the UC Davis GMP Facility.

Generation
of GMP Standard Operating Procedures (SOPs).

Manufacturing
and cryopreservation of the vaccine cell
line (400 vials with 15 million cells / vial).

Manufacturing
and cryopreservation of the control cell line (100 vials with 2 million cells/ vial).

Quality
control and release tests on the cells, generation of appropriate documentation.

Storage.
of the cryopreserved vaccine and control cell line vials for 1 year.

Shipping
of the vaccine and control cell line vials (4 shipments estimated).

 

II. COMPENSATION

 

A.
Rates

 

Approved
GMP facility rate for non UC customers: $500 / hour

 

Transfer
of technology and procedures from BriaCell to the UC Davis GMP facility:

GMP
facility time required: 2 hours = $1,000

 

Generation
of GMP Standard Operating Procedures (SOPs):

GMP
facility time required: 4 hours = $2,000

 

Manufacturing
and cryopreservation of the vaccine cell line (400 vials with 15 million cells / vial):

GMP
facility time required: 24 hours = $12,000

 

Manufacturing
and cryopreservation of the control cell line (100 vials with 2 million cells / vial):

GMP
facility time required: 8 hours = $4,000

 

    	Page 9 of 11

    	 

    

 

Quality
control and release tests on the cells, generation of appropriate documentation:

 

14
day sterility assay (21 CFR) for outside customers: $120.79 per assay

LAL
Endotoxin assay for outside customers: $358.52 per assay 

Mycoplasma
PCR for outside customers: $250 per assay

 

14
day sterility on the vaccine cell line:

1
assay on incoming master cell bank, 4 assays as release tests (1 percent of the final product vials), 5 assays total: $603.95

 

14
day sterility on the control cell line:

1
assay on incoming master cell bank, 1 assay as release test (1 percent of the final product vials), 2 assays total: $241.58

 

LAL
Endotoxin assay on the vaccine cell line:

1
assay on incoming master cell bank, 4 assays as release tests (1 percent of the final product vials), 5 assays total: $1,792.60

 

LAL
Endotoxin assay on the control cell line:

1
assay on incoming master cell bank, 1 assay as release test (1 percent of the final product vials), 2 assays total: $717.04

 

Mycoplasma
PCR on the vaccine cell line:

1
assay on incoming master cell bank, 4 assays as release tests (1 percent of the final product vials), 5 assays total: $1250.95

 

Mycoplasma
PCR on the control cell line:

1
assay on incoming master cell bank, 1 assay as release test (1 percent of the final product vials), 2 assays total: $500

 

REMARK:
MYCOPLASMA CULTURE (Send out test): TBD, not included in this price quotation.

 

Generation
of appropriate documentation (Certificates of Analysis):

GMP
facility time required: 2 hours= $1,000

 

Storage
of the cryopreserved vaccine and control cell line vials:

1
year of storage: GMP facility time required: 8 hours = $4,000

 

Shipping
of the vaccine and control cell line vials:

GMP
facility time required per shipment (including chain of custody documentation): 1 hour= $500

 

    	Page 10 of 11

    	 

    

 

Shipping
cost through Fedex: Dependent on shipment size, but estimated at $350 per shipment. 

4
shipments estimated: GMP facility time: $2,000, Fedex charge: $1,400.

 

Estimated
materials and reagents costs:

Media,
Fetal Bovine Serum, glutamine, flasks, plasticware, other disposables: $10,000

 

REMARK:
Materials and reagents costs are estimates only and may vary.

 

*Grand
total, including estimated materials and reagents costs: $42,506.12

 

B.
Payment Schedule:

 

UNIVERSITY
shall submit invoices to COMPANY in the amount of Forty Two Thousand Five Hundred Six Dollars and Twelve Cents ($42,506.12). The
payment schedule will take the following form:

 

	A.
    First upfront payment:	 	$	21,253.06	 
	B.
    Second payment after completion of Services:	 	$	21,253.06	 
	C.
    Grand Total*:	 	$	42,506.12	 

 

COMPANY
agrees to remit payments in full by check no later than thirty (30) calendar days from date indicated in said invoices.

 

*UNIVERSITY
reserves the right to review the cost for each manufacturing vaccine and cell line, if necessary adjust such costs. Such cost
adjustments shall be communicated by UNIVERSITY to COMPANY at least thirty (30) days in advance.

 

    	Page 11 of 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]